ESMO’s new ELCAP guidance, published in Annals of Oncology, distills 23 consensus statements from 20 experts to safely ...

Findings from the Phase 3 ASCENT-03 trial, presented at ESMO 2025, demonstrated that sacituzumab govitecan (Trodelvy®) ...

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

AstraZeneca has reached a wide-ranging agreement with the Trump administration to cut prescription drug prices for American patients—offering up to 80% discounts via TrumpRx.gov—while investing $50 ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s anti–PD-1 therapy pembrolizumab (KEYTRUDA®), potentially expanding ...

Results from the phase III evERA trial show that giredestrant in combination with everolimus significantly prolonged progression-free survival in ER+, HER2- advanced breast cancer following prior CDK4 ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

The third-generation tyrosine kinase inhibitor olverembatinib may represent a major advance for patients with chronic myeloid leukemia and Philadelphia chromosome (Ph+) positive acute lymphoblastic ...

ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...

Roche has announced that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Elecsys pTau217 blood test for the diagnosis of Alzheimer’s disease. This ...

Johnson & Johnson announced the acquisition of Ambrx Biopharma for $2 billion, aiming to boost its oncology pipeline with Ambrx's innovative antibody drug conjugates. This strategic move focuses on ...